✦ LIBER ✦

Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer

✍ Scribed by Rodolfo Passalacqua; Carlo Buzio; Sebastiano Buti; Camillo Porta; Roberto Labianca; Debora Pezzuolo; Roberta Camisa; Roberto Sabbatini; Luigi Benecchi; Caterina Messina; Rita Cengarle; Augusto Vaglio; Matteo Dalla Chiesa; Gianluca Tomasello; Caterina Caminiti

Publisher: Springer-Verlag
Year: 2009
Tongue: English
Weight: 284 KB
Volume: 59
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s00262-009-0773-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of 5-fluorouracil, interf

Phase II trial of 5-fluorouracil, interferon-α and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma

✍ Julie A. Ellerhorst; Avishay Sella; Robert J. Amato; Shi-Ming Tu; Randall E. Mil 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## RESULTS. Fifty-five patients were enrolled in the trial and 52 were evaluable for ogy, The University of Texas M. D. Anderson response. All patients experienced fever and flu-like symptoms. Grade 3 or 4 nonhe-Cancer Center, Houston, Texas. matologic toxic effects included hypertension (48%), d

Long-term immunotherapy with low-dose in

Long-term immunotherapy with low-dose interleukin-2 and interferon-α in the treatment of patients with advanced renal cell carcinoma

✍ Carlo Buzio; Simeone Andrulli; Rosaria Santi; Laura Pavone; Rodolfo Passalacqua; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

Long-term treatment with low doses of in

Long-term treatment with low doses of interleukin-2 and interferon-α: immunological effects in advanced renal cell cancer

✍ Laura Pavone; Simeone Andrulli; Rosaria Santi; Maria Majori; Carlo Buzio 📂 Article 📅 2001 🏛 Springer-Verlag 🌐 English ⚖ 184 KB

A phase I clinical trial of low-dose int

A phase I clinical trial of low-dose interferon-α-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma

✍ Robert J. Amato; Muhammad Khan 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 221 KB

Clinical outcome of combined immunothera

Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-α for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report

✍ Hideaki Miyake; Isao Hara; Iori Sakai; Ken-ichi Harada; Taka-aki Inoue; Hiroshi 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 244 KB

A Phase II trial of intravenous gemcitab

A Phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma

✍ Christopher W. Ryan; Nicholas J. Vogelzang; Walter M. Stadler 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

## Abstract ## BACKGROUND The objective of this study was to determine the response rate and toxicity of gemcitabine and continuous‐infusion 5‐fluorouracil (5‐FU) in combination with subcutaneous interleukin‐2 (IL2) and interferon‐α (IFNA) in patients with metastatic renal cell carcinoma. ## METH